JP2009523156A - 癌の処置のためのγ線照射と組み合わせた化合物の使用 - Google Patents

癌の処置のためのγ線照射と組み合わせた化合物の使用 Download PDF

Info

Publication number
JP2009523156A
JP2009523156A JP2008549886A JP2008549886A JP2009523156A JP 2009523156 A JP2009523156 A JP 2009523156A JP 2008549886 A JP2008549886 A JP 2008549886A JP 2008549886 A JP2008549886 A JP 2008549886A JP 2009523156 A JP2009523156 A JP 2009523156A
Authority
JP
Japan
Prior art keywords
compound
alkyl
use according
tppii
unbranched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008549886A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009523156A5 (cg-RX-API-DMAC10.html
Inventor
リカルド グラス
ホン シュー
Original Assignee
オンコレー アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オンコレー アーベー filed Critical オンコレー アーベー
Publication of JP2009523156A publication Critical patent/JP2009523156A/ja
Publication of JP2009523156A5 publication Critical patent/JP2009523156A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2008549886A 2006-01-13 2007-01-15 癌の処置のためのγ線照射と組み合わせた化合物の使用 Pending JP2009523156A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75908806P 2006-01-13 2006-01-13
US60/759,088 2006-01-13
PCT/EP2007/050363 WO2007080194A2 (en) 2006-01-13 2007-01-15 Use of tpp ii inhibitors in combination with gamma-irradiation for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2009523156A true JP2009523156A (ja) 2009-06-18
JP2009523156A5 JP2009523156A5 (cg-RX-API-DMAC10.html) 2010-02-25

Family

ID=36609604

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008549886A Pending JP2009523156A (ja) 2006-01-13 2007-01-15 癌の処置のためのγ線照射と組み合わせた化合物の使用
JP2008549887A Pending JP2009523157A (ja) 2006-01-13 2007-01-15 虚血および神経変性の処置のための化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008549887A Pending JP2009523157A (ja) 2006-01-13 2007-01-15 虚血および神経変性の処置のための化合物

Country Status (8)

Country Link
US (2) US20100168038A1 (cg-RX-API-DMAC10.html)
EP (2) EP1971357A2 (cg-RX-API-DMAC10.html)
JP (2) JP2009523156A (cg-RX-API-DMAC10.html)
KR (1) KR20080085035A (cg-RX-API-DMAC10.html)
CN (1) CN101370509A (cg-RX-API-DMAC10.html)
AU (1) AU2007204314A1 (cg-RX-API-DMAC10.html)
CA (1) CA2636533A1 (cg-RX-API-DMAC10.html)
WO (2) WO2007088099A2 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009000296A2 (en) * 2007-06-25 2008-12-31 Oncoreg Ab Tpp ii inhibitors for use in the treatment of autoimmune and inflammatory diseases and transplant rejection
WO2009000297A1 (en) * 2007-06-25 2008-12-31 Oncoreg Ab Tpp ii inhibitors for use in combination with chemotherapy for the treatment of cancer
US8779002B2 (en) * 2007-10-15 2014-07-15 Salk Institute For Biological Studies Methods for treating a variety of diseases and conditions, and compounds useful therefor
MY159958A (en) * 2009-12-18 2017-02-15 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
WO2011159685A2 (en) * 2010-06-16 2011-12-22 The Regents Of The University Of Michigan Inhibition of wdr5 interaction with its binding partners and therapeutic methods
CA2822442C (en) * 2010-12-22 2021-03-16 The Salk Institute For Biological Studies Cyclic crf antagonist peptides
WO2015040235A1 (en) 2013-09-23 2015-03-26 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Anti-inflammatory tripeptides
JP2017525684A (ja) * 2014-07-24 2017-09-07 ノーレックス インコーポレイテッド N−メチル−d−アスパラギン酸受容体モジュレーターならびにその製造方法及び使用方法
CN111603560A (zh) * 2020-06-22 2020-09-01 泉州台商投资区秋鑫茶业有限公司 茶叶γ-氨基丁酸在肿瘤放射治疗上的应用
JP2024510435A (ja) 2021-03-18 2024-03-07 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06504035A (ja) * 1990-08-22 1994-05-12 トリペプ アクチボラゲット ヒト免疫不全ウィルス感染を阻止するペプチドとその使用法
JP2003506410A (ja) * 1999-08-09 2003-02-18 トリペップ アクチ ボラゲット ウィルス感染性を阻止するペプチドおよびその使用方法
JP2004531480A (ja) * 2001-02-05 2004-10-14 ノイロテル・アーゲー 神経変性疾患の処置のためのトリペプチド誘導体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627035A (en) * 1990-08-22 1997-05-06 Syntello Vaccine Development Ab Peptides that block human immunodeficiency virus and methods of use thereof
JP3943332B2 (ja) * 1997-12-23 2007-07-11 アンスティテュ ナシオナル ドゥ ラ サントゥ エ ドゥ ラ ルシェルシェ メディカル(イーエヌエスエーエールエム) トリペプチジルペプチダーゼインヒビター
EP1436317A1 (en) * 2001-09-19 2004-07-14 Tripep Ab Molecules that block viral infectivity and methods of use thereof
US20040097422A1 (en) * 2002-06-14 2004-05-20 Karl Munger Methods of use for tripeptidyl peptidase II inhibitors as anticancer agents
EP1716247A1 (en) * 2004-01-31 2006-11-02 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with tripeptidyl-peptidase 2 (tpp2)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06504035A (ja) * 1990-08-22 1994-05-12 トリペプ アクチボラゲット ヒト免疫不全ウィルス感染を阻止するペプチドとその使用法
JP2003506410A (ja) * 1999-08-09 2003-02-18 トリペップ アクチ ボラゲット ウィルス感染性を阻止するペプチドおよびその使用方法
JP2004531480A (ja) * 2001-02-05 2004-10-14 ノイロテル・アーゲー 神経変性疾患の処置のためのトリペプチド誘導体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6012029641; J. Med. Chem. Vol.43, No.4, 2000, 664-674 *
JPN6012029642; Tetrahedron Vol.50, No.21, 1994, p.6333-46 *
JPN6012029643; Bulletin of Experimental Biology and Medicine Vol.136, No.4, 2003, p.319-322 *

Also Published As

Publication number Publication date
AU2007204314A1 (en) 2007-07-19
US20100168038A1 (en) 2010-07-01
WO2007080194A3 (en) 2008-02-14
KR20080085035A (ko) 2008-09-22
JP2009523157A (ja) 2009-06-18
CA2636533A1 (en) 2007-07-19
WO2007080194A2 (en) 2007-07-19
EP1971357A2 (en) 2008-09-24
CN101370509A (zh) 2009-02-18
WO2007088099A2 (en) 2007-08-09
WO2007088099A3 (en) 2007-11-08
US20090227521A1 (en) 2009-09-10
EP2160196A2 (en) 2010-03-10

Similar Documents

Publication Publication Date Title
US20100168038A1 (en) Use of compounds in combination with gamma-irradiation for the treatment of cancer
CN102245632B (zh) Muc-1胞质结构域肽作为癌症的抑制剂
US20230077821A1 (en) BCL-W Polypeptides and Mimetics for Treating or Preventing Chemotherapy-Induced Peripheral Neuropathy and Hearing Loss
JP4843095B2 (ja) 血管内皮増殖因子受容体1に由来するエピトープ・ペプチドおよびこれらのペプチドを含むワクチン
AU2016230125A1 (en) Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells
WO2012051207A2 (en) FRAGMENT OF SECRETED HEAT SHOCK PROTEIN-90ALPHA (Hsup90ALPHA) AS VACCINES OR EPITOPE FOR MONOCLONAL ANTIBODY DRUGS OR TARGET FOR SMALL MOLECULE DRUGS AGAINST A RANGE OF SOLID HUMAN TUMORS
KR20110139256A (ko) Sparc 혈관형성 영역과 사용방법
UA110119C2 (xx) Пептиди tomm34 та вакцини, що їх містять
US20100240591A1 (en) Tpp ii inhibitors for use in the treatment of autoimmune and inflammatory diseases and transplant rejection
US8940701B2 (en) Compounds for, and methods of, treating cancer and inhibiting invasion and metastases
JP2017505755A (ja) 転移がんの治療および予防のための医薬組成物および方法
WO2009000297A1 (en) Tpp ii inhibitors for use in combination with chemotherapy for the treatment of cancer
JP7291327B2 (ja) ペプチド誘導体及びそれを含む医薬組成物
US20080045463A1 (en) Methods For Lowering Hif-1 Mediated Gene Expression
WO2013009165A1 (en) A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine
US20240247031A1 (en) Composition for treating cancer containing telomerase-targeting gnrh antagonist-derived peptide hs1002
Shevtsov et al. Therapeutic implications of heat shock proteins in cancer
JP2019510015A (ja) Bcl−2 l10/ip3受容体の相互作用の阻害剤
KR20130010477A (ko) Sparc 혈관형성 영역과 사용방법
WO2003095484A2 (en) Polypeptides increasing p53 expression

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120612

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121106